{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:31:03Z","timestamp":1790112663386,"version":"4.0.1"},"reference-count":157,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012465","name":"Nemours Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012465","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences of the National Institutes of Health","doi-asserted-by":"publisher","award":["P20GM103446"],"award-info":[{"award-number":["P20GM103446"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences of the National Institutes of Health","doi-asserted-by":"publisher","award":["U54GM104941"],"award-info":[{"award-number":["U54GM104941"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025212","name":"State of Delaware","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100025212","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["EB032025"],"award-info":[{"award-number":["EB032025"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Radiopharmaceutical therapy (RPT) has emerged as a transformative modality in oncology, particularly for patients with metastatic or inoperable tumors. By leveraging molecularly targeted carriers conjugated to cytotoxic radionuclides, RPT enables precise delivery of ionizing radiation to tumor sites while minimizing off-target effects. Central to this approach are alpha (\u03b1) and beta (\u03b2) particle-emitting radionuclides. This review aims to provide a comprehensive overview of all clinically relevant alpha and beta emitters and incorporates the most recent advances from 2017\u20132025, offering a comprehensive and up-to-date perspective. Alpha and beta emitters hold significant promises for the future, especially in nuclear medicine, energy, and environmental monitoring. Medically, these emitters are at the forefront of targeted radiotherapy, offering new hope for cancer treatment. Alpha emitters such as Actinium-225 and Radium-223 are gaining attention for their high linear energy transfer, which allows them to effectively kill cancer cells while minimizing damage to surrounding healthy tissues. Beta emitters, including Lutetium-177 and Iodine-131, are already widely used for treating thyroid cancer, neuroendocrine tumors, and prostate cancer. They offer a longer range in tissue penetration than alpha particles, making them suitable for larger or more diffuse tumors. Alpha and beta emitters hold tremendous promise in targeted radiotherapy. However, current research is limited by an incomplete understanding of resistance pathways, insufficient long-term safety and efficacy data, and underdeveloped personalized treatment frameworks. As production technologies improve and safety protocols advance, these emitters will likely play an even more prominent role in both health care and scientific innovation.<\/jats:p>","DOI":"10.3390\/ijms27052290","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:39:56Z","timestamp":1772455196000},"page":"2290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction"],"prefix":"10.3390","volume":"27","author":[{"given":"Hanieh","family":"Karimi","sequence":"first","affiliation":[{"name":"Department of Radiology, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Diagnostic & Research PET\/MR Center, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Shaffer","sequence":"additional","affiliation":[{"name":"Nemours Biomedical Research, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stauff","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Diagnostic & Research PET\/MR Center, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay V. R.","family":"Kandula","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi H.","family":"Kecskemethy","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Diagnostic & Research PET\/MR Center, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren W.","family":"Averill","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Diagnostic & Research PET\/MR Center, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-6392","authenticated-orcid":false,"given":"Xuyi","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Diagnostic & Research PET\/MR Center, Nemours Children\u2019s Health, Wilmington, DE 19803, USA"},{"name":"Department of Radiology, Thomas Jefferson University, Philadelphia, PA 19107, USA"},{"name":"Department of Psychological and Brain Sciences, University of Delaware, Newark, DE 19716, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo, and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhang, S., Zhang, A., Qi, X., Han, Z., Song, L., Zhou, J., Wang, G., Zhu, R., and Li, J. (2025). Radionuclide-labeled biomaterials: A novel strategy for tumor-targeted therapy. Biomimetrics, 10.","DOI":"10.3390\/biomimetics10060394"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0000000000000528","article-title":"Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: Practical management issues for patient selection","volume":"42","author":"Den","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s11912-023-01458-6","article-title":"Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer: Combination strategies","volume":"25","author":"Arbuznikova","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3724\/abbs.2024206","article-title":"Astatine-211 and actinium-225: Two promising nuclides in targeted alpha therapy: 211At and 225Ac radiopharmaceuticals and their applications","volume":"57","author":"Zuo","year":"2024","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1111\/jne.70013","article-title":"Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors","volume":"37","author":"Santo","year":"2025","journal-title":"J. Neuroendocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: Current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lepareur, N. (2025). An overview of current phase 3 radiopharmaceutical therapy clinical trials. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1549676"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: A review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vikas, P., Borcherding, N., Chennamadhavuni, A., and Garje, R. (2020). Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00570"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Peyraud, F., and Italiano, A. (2020). Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers, 12.","DOI":"10.3390\/cancers12061502"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Marshall, H.T., and Djamgoz, M.B. (2018). Immuno-oncology: Emerging targets and combination therapies. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00315"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hameed, M.Y., Gul, M., Chaudhry, A., Muzaffar, H., Sheikh, M., Chee, W., Ayyash, S., Ayyash, J., Al-Hindi, M., and Shahare, H. (2024). From oncogenesis to theranostics: The transformative role of PSMA in prostate cancer. Cancers, 16.","DOI":"10.3390\/cancers16173039"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/bjr\/tqae092","article-title":"Imaging and therapy in prostate cancer using prostate-specific membrane antigen radioligands","volume":"97","author":"Naik","year":"2024","journal-title":"Br. J. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-emitters for radiotherapy: From basic radiochemistry to clinical studies-part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.30574\/gscarr.2021.7.1.0043","article-title":"Fundamental characteristics and application of radiation","volume":"7","author":"Karmaker","year":"2021","journal-title":"GSC Adv. Res. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"035016","DOI":"10.1088\/1361-6560\/abd3ef","article-title":"Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow","volume":"66","author":"Tranel","year":"2021","journal-title":"Phys. Med. Biol."},{"key":"ref_19","first-page":"1573","article-title":"Biological effects of ionizing radiation","volume":"12","year":"2025","journal-title":"Hosp. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","article-title":"Alpha-emitters and targeted alpha therapy in oncology: From basic science to clinical investigations","volume":"13","author":"Makvandi","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kang, H., Min, S., Seo, B., Roh, C., Hong, S., and Cheong, J.H. (2020). Low energy beta emitter measurement: A review. Chemosensors, 8.","DOI":"10.3390\/chemosensors8040106"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Li, K., and Hong, M. (2022). Radiation-induced bystander effect and cytoplasmic irradiation studies with microbeams. Biology, 11.","DOI":"10.3390\/biology11070945"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tang, H., Cai, L., He, X., Niu, Z., Huang, H., Hu, W., Bian, H., and Huang, H. (2023). Radiation-induced bystander effect and its clinical implications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1124412"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Nelson, B.J., Andersson, J.D., and Wuest, F. (2020). Targeted alpha therapy: Progress in radionuclide production, radiochemistry, and applications. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010049"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/j.semnuclmed.2019.11.003","article-title":"Targeted \u03b1-emitter therapy of neuroendocrine tumors","volume":"50","author":"Kunikowska","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13566-017-0315-6","article-title":"Intratumoral treatment with radioactive beta-emitting microparticles: A systematic review","volume":"6","author":"Bakker","year":"2017","journal-title":"J. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bogdanovic, B., Hugonnet, F., and Montemagno, C. (2025). Theranostics in hematological malignancies: Cutting-edge advances in diagnosis and targeted therapy. Cancers, 17.","DOI":"10.3390\/cancers17071247"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: A review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2967\/jnmt.121.262294","article-title":"Radiation safety considerations and clinical advantages of \u03b1-emitting therapy radionuclides","volume":"50","author":"Serencsits","year":"2022","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41181-023-00230-2","article-title":"Position paper to facilitate patient access to radiopharmaceuticals: Considerations for a suitable pharmaceutical regulatory framework","volume":"9","author":"Korde","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/0300891619851376","article-title":"Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: When and why","volume":"105","author":"Gallicchio","year":"2019","journal-title":"Tumori J."},{"key":"ref_32","first-page":"61","article-title":"Utility of F-18 FDG PET\/CT for detection of bone marrow metastases in prostate cancer patients treated with radium-223","volume":"6","author":"Maruyama","year":"2018","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ma, J., Li, L., Liao, T., Gong, W., and Zhang, C. (2022). Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.796657"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00259-025-07153-x","article-title":"Reflective analysis on the current 131I adjuvant therapy indications in intermediate-and high-risk differentiated thyroid cancer","volume":"52","author":"Sun","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Auttara-Atthakorn, A., Sungmala, J., Anothaisintawee, T., Reutrakul, S., and Sriphrapradang, C. (2022). Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.960265"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: Analysis of outcome, safety, and their determinants","volume":"111","author":"Welin","year":"2021","journal-title":"Neuroendocrinology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin eeceptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bongiovanni, A., Nicolini, S., Ibrahim, T., Foca, F., Sansovini, M., Di Paolo, A., Grassi, I., Liverani, C., Calabrese, C., and Ranallo, N. (2022). 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of Phase II prospective clinical trials. Cancers, 14.","DOI":"10.3390\/cancers14246022"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2019-129391","article-title":"Long-term outcome of patients with low-grade follicular lymphoma treated with yttrium-90 ibritumomab tiuxetan: The Mayo Clinic experience","volume":"134","author":"Moustafa","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bbmt.2017.03.004","article-title":"Phase II study of yttrium-90 ibritumomab tiuxetan plus high-dose BCNU, etoposide, cytarabine, and melphalan for non-Hodgkin lymphoma: The role of histology","volume":"23","author":"Krishnan","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lewis, J., Windhorst, A., and Zeglis, B. (2019). The radiopharmaceutical chemistry of alpha-emitting radionuclides. Radiopharmaceutical Chemistry, Springer.","DOI":"10.1007\/978-3-319-98947-1"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Miederer, M., Bene\u0161ov\u00e1-Sch\u00e4fer, M., Mamat, C., Kaestner, D., Pretze, M., Michler, E., Brogsitter, C., Kotzerke, J., Kopka, K., and Scheinberg, D.A. (2024). Alpha-emitting radionuclides: Current status and future perspectives. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010076"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e30813","DOI":"10.1016\/j.heliyon.2024.e30813","article-title":"Non-targeted effects of radiation therapy for glioblastoma","volume":"10","author":"Lerouge","year":"2024","journal-title":"Heliyon"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.semnuclmed.2018.02.008","article-title":"Radiation imagers for quantitative, single-particle digital autoradiography of alpha-and beta-particle emitters","volume":"48","author":"Miller","year":"2018","journal-title":"Semin. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/02841860802245163","article-title":"Beta emitters and radiation protection","volume":"48","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Salih, S., Alkatheeri, A., Alomaim, W., and Elliyanti, A. (2022). Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. Molecules, 27.","DOI":"10.3390\/molecules27165231"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101543","DOI":"10.1016\/j.tranon.2022.101543","article-title":"Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines","volume":"26","author":"Abramenkovs","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"18489","DOI":"10.1038\/s41598-019-54884-7","article-title":"Radiobiological effects of the alpha emitter Ra-223 on tumor cells","volume":"9","author":"Bannik","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.21873\/anticanres.15568","article-title":"Ra-223 and ethinylestradiol combination therapy in castration-resistant prostate cancer","volume":"42","author":"Shimada","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cam4.2780","article-title":"Phase II study of radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41391-025-00969-6","article-title":"Real-world utilization patterns and survival in men with metastatic prostate cancer treated with radium-223 in the United States","volume":"28","author":"Raval","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"462","DOI":"10.21873\/cdp.10129","article-title":"Appropriate patient status for Ra-223 treatment in the treatment sequence for castration-resistant prostate cancer","volume":"2","author":"Ito","year":"2022","journal-title":"Cancer Diagn. Progn."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: The RAVENS phase II randomized trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1007\/s00259-025-07256-5","article-title":"Cancer-control outcomes of radium-223-pretreated lutetium-177-PSMA radioligand vs. radium-223-na\u00efve mCRPC patients","volume":"52","author":"Wenzel","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40658-021-00410-6","article-title":"Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: A pharmacokinetic modeling analysis","volume":"8","author":"Sgouros","year":"2021","journal-title":"EJNMMI Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1535-7163.MCT-21-1021","article-title":"Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HER2pos cancer","volume":"21","author":"Rodak","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Salvanou, E.-A., Stellas, D., Tsoukalas, C., Mavroidi, B., Paravatou-Petsotas, M., Kalogeropoulos, N., Xanthopoulos, S., Denat, F., Laurent, G., and Bazzi, R. (2020). A proof-of-concept study on the therapeutic potential of au nanoparticles radiolabeled with the alpha-emitter actinium-225. Pharmaceutics, 2.","DOI":"10.3390\/pharmaceutics12020188"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00259-024-06809-4","article-title":"Evaluating [225Ac] Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice","volume":"51","author":"Taddio","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"225 Ac-PSMA-617\/177 Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: Pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/pros.24857","article-title":"The safety and efficacy of targeted alpha therapy, Ac-225 prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"85","author":"Besiroglu","year":"2025","journal-title":"Prostate"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: A pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen\u2013targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: A phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.122.263962","article-title":"Cure of micrometastatic B-cell lymphoma in an SCID mouse model using 213Bi-anti-CD20 monoclonal antibody","volume":"64","author":"Havlena","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13550-017-0283-2","article-title":"Therapeutic efficacy of \u03b1-radioimmunotherapy with different activity levels of the 213 Bi-labeled monoclonal antibody MX35 in an ovarian cancer model","volume":"7","author":"Aneheim","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.208611","article-title":"Radiolabeled antibodies against m\u00fcllerian-inhibiting substance receptor, type II: New tools for a theranostic approach in ovarian cancer","volume":"59","author":"Deshayes","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1158\/1078-0432.CCR-18-3295","article-title":"Drugs that modify cholesterol metabolism alter the p38\/JNK-mediated targeted and nontargeted response to alpha and auger radioimmunotherapy","volume":"2","author":"Ladjohounlou","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Jiao, R., Allen, K., Malo, M., Rickles, D., and Dadachova, E. (2020). Evaluating the combination of radioimmunotherapy and immunotherapy in a melanoma mouse model. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030773"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-018-4015-2","article-title":"Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue","volume":"45","author":"Krolicki","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Kauffman, N., Singh, S.K., Morrison, J., and Zinn, K.R. (2023). Effective therapy with bismuth-212 labeled macroaggregated albumin in orthotopic mouse breast tumor models. Front. Chem., 11.","DOI":"10.3389\/fchem.2023.1204872"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jlcr.4121","article-title":"Lead-212\/bismuth-212 in vivo generator based on ultrasmall silver telluride nanoparticles","volume":"67","author":"Wang","year":"2024","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Huang, X., Kaneda-Nakashima, K., Kadonaga, Y., Kabayama, K., Shimoyama, A., Ooe, K., Kato, H., Toyoshima, A., Shinohara, A., and Haba, H. (2022). Astatine-211-labeled gold nanoparticles for targeted alpha-particle therapy via intravenous injection. Pharmaceutics, 14.","DOI":"10.21203\/rs.3.rs-2110991\/v1"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00963-9","article-title":"Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy","volume":"19","author":"Kato","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_75","first-page":"1","article-title":"Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors","volume":"10","author":"Jennbacken","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-023-06457-0","article-title":"Development of probes for radiotheranostics with albumin binding moiety to increase the therapeutic effects of astatine-211 (211At)","volume":"51","author":"Echigo","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1535-7163.MCT-18-1103","article-title":"Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model","volume":"18","author":"Stallons","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kasten, B.B., Oliver, P.G., Kim, H., Fan, J., Ferrone, S., Zinn, K.R., and Buchsbaum, D.J. (2018). (212)Pb-labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040925"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","article-title":"212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models","volume":"58","author":"Kasten","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Maaland, A.F., Saidi, A., Torgue, J., Heyerdahl, H., Stallons, T.A.R., Kolstad, A., and Dahle, J. (2020). Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230526"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","article-title":"Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab","volume":"41","author":"Meredith","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17800","DOI":"10.1038\/s41598-019-54150-w","article-title":"Alpha-PET for prostate cancer: Preclinical investigation using 149Tb-PSMA-617","volume":"9","author":"Umbricht","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41181-016-0008-2","article-title":"Alpha-PET with terbium-149: Evidence and perspectives for radiotheragnostics","volume":"1","author":"Vermeulen","year":"2017","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e002387","DOI":"10.1136\/jitc-2021-002387","article-title":"Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy","volume":"9","author":"Lejeune","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Berg-Larsen, A., Mobergslien, A., Moen, I., Petros, G., Kristian, A., Gunvaldsen, K.S., Cruciani, V., Wickstroem, K., Bjerke, R.M., and Karlsson, J. (2022). Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1033303"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Karlsson, J., Schatz, C.A., Wengner, A.M., Hammer, S., Scholz, A., Cuthbertson, A., Wagner, V., Hennekes, H., Jardine, V., and Hagemann, U.B. (2023). Targeted thorium-227 conjugates as treatment options in oncology. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1071086"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1078-0432.CCR-19-2268","article-title":"Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer","volume":"26","author":"Hammer","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"56311","DOI":"10.18632\/oncotarget.16910","article-title":"Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma","volume":"8","author":"Hagemann","year":"2017","journal-title":"Oncotarget"},{"key":"ref_90","first-page":"497","article-title":"Advances in precision oncology: Targeted thorium-227 conjugates as a new modality in targeted alpha therapy","volume":"34","author":"Hagemann","year":"2020","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1038\/s41598-022-17185-0","article-title":"Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma","volume":"12","author":"Malone","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"799","DOI":"10.21037\/jgo.2017.08.03","article-title":"Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: A retrospective study","volume":"8","author":"Mantry","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1007\/s12325-024-02800-5","article-title":"Selective internal radiation therapy using Y-90 resin microspheres for metastatic colorectal cancer: An updated systematic review and network meta-analysis","volume":"41","author":"Agirrezabal","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jvir.2018.09.020","article-title":"Radioembolization with yttrium-90 microspheres for the treatment of liver metastases of pancreatic adenocarcinoma: A multicenter analysis","volume":"30","author":"Kim","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jvir.2023.10.015","article-title":"Partition dosimetry and outcomes of metastatic neuroendocrine tumors after yttrium-90 resin microsphere radioembolization","volume":"35","author":"Doyle","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11547-020-01240-9","article-title":"Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients","volume":"126","author":"Bozkurt","year":"2021","journal-title":"Radiol. Med."},{"key":"ref_97","first-page":"5104082","article-title":"Efficacy and prognostic factors for Y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases","volume":"2020","author":"Tsang","year":"2020","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"1","author":"Frilling","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"110043","DOI":"10.1016\/j.msec.2019.110043","article-title":"177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer","volume":"105","year":"2019","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/acs.molpharmaceut.2c00815","article-title":"Treatment of orthotopic U251 human glioblastoma multiforme tumors in NRG mice by convection-enhanced delivery of gold nanoparticles labeled with the \u03b2-particle-emitting radionuclide, 177Lu","volume":"20","author":"Georgiou","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.122.264850","article-title":"[177Lu]Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: Dosimetry results and critical statement","volume":"64","author":"Graef","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_102","unstructured":"(2025, December 08). European Association of Nuclear Medicine Guidelines. Available online: https:\/\/eanm.org\/publications\/guidelines\/overview\/."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-018-0427-z","article-title":"Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA 0, Tyr 3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: Investigation of a new hybrid image approach","volume":"8","author":"Gosewisch","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"113668","DOI":"10.1016\/j.biopha.2022.113668","article-title":"Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer","volume":"155","author":"Chang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12149-019-01376-3","article-title":"The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival","volume":"33","author":"Acar","year":"2019","journal-title":"Ann. Nucl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Huynh, T.T., van Dam, E.M., Sreekumar, S., Mpoy, C., Blyth, B.J., Muntz, F., Harris, M.J., and Rogers, B.E. (2022). Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer. Pharmaceuticals, 15.","DOI":"10.3390\/ph15060728"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1038\/s41598-021-82812-1","article-title":"Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT","volume":"11","author":"Hao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2967\/jnumed.120.243543","article-title":"Peptide receptor radionuclide therapy with 67Cu-CuSarTATE is highly efficacious against a somatostatin-positive neuroendocrine tumor model","volume":"61","author":"Cullinane","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00259-024-06648-3","article-title":"Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer","volume":"51","author":"Ketchemen","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s12149-017-1188-x","article-title":"I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: Comparison between recombinant human TSH administration and thyroid hormone withdrawal","volume":"31","author":"Hong","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12020-021-02657-6","article-title":"The effect of I-131 therapy on pregnancy outcomes after thyroidectomy in patients with differentiated thyroid carcinoma: A meta-analysis","volume":"73","author":"Zhang","year":"2021","journal-title":"Endocrine"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"He, H., Xu, Q., and Yu, C. (2022). The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: A meta-analysis. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09329-2"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Mester, A., Piciu, A., Piciu, D., Petean, I., Lucaciu, P.O., Apostu, D., Moisescu-Goia, C., Voina-Tonea, A., and Moldovan, M. (2020). Disorders of dental hard tissues induced by radioiodine-131 (I-131) therapy used in differentiated thyroid cancer: An in vitro study. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110475"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/jlcr.3622","article-title":"Aligning physics and physiology: Engineering antibodies for radionuclide delivery","volume":"61","author":"Tsai","year":"2018","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_118","first-page":"437","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09553002.2018.1440092","article-title":"Mechanisms of inflammatory responses to radiation and normal tissues toxicity: Clinical implications","volume":"94","author":"Najafi","year":"2018","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jlcr.3612","article-title":"Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy\u2014Model, vector, and radionuclide selection","volume":"61","author":"Carter","year":"2018","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"George, S.C., and Samuel, E.J.J. (2023). Developments in 177Lu-based radiopharmaceutical therapy and dosimetry. Front. Chem., 11, Erratum in Front Chem. 2024, 12, 1410803.","DOI":"10.3389\/fchem.2023.1218670"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine tumor therapy: 177Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/10428194.2023.2295792","article-title":"The asymptomatic follicular lymphoma (AFL) trial: Single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma","volume":"65","author":"Laoruangroj","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-18-3755","article-title":"Multicenter, open-label, phase II study of bendamustine and rituximab followed by 90-yttrium (Y) ibritumomab tiuxetan for untreated follicular lymphoma (Fol-BRITe)","volume":"25","author":"Lansigan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00259-019-04475-5","article-title":"Radium-223 dichloride in prostate cancer: Proof of principle for the use of targeted alpha treatment in clinical practice","volume":"47","author":"Dizdarevic","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Alshehri, A.H. (2024). Bone-targeting radionuclides in the treatment of metastatic castration-resistant prostate cancer: A review on radium-223 chloride (alpharadin) in combination with other therapies. Diagnostics, 14.","DOI":"10.3390\/diagnostics14212407"},{"key":"ref_127","first-page":"1680","article-title":"The applications of radioisotopes in modern medicine: A review of diagnostic, therapeutic, and research advancements","volume":"3","author":"Abubakr","year":"2024","journal-title":"ERU Res. J."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/ntno.64141","article-title":"Radiotheranostics-precision medicine in nuclear medicine and molecular imaging","volume":"6","author":"Duan","year":"2022","journal-title":"Nanotheranostics"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.55544\/jrasb.2.6.26","article-title":"Targeted therapies in cancer treatment: Unveiling the latest breakthroughs and promising approaches","volume":"2","author":"Rai","year":"2024","journal-title":"J. Res. Appl. Sci. Biotechnol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40001-023-01627-0","article-title":"Radiopharmaceuticals: Navigating the frontier of precision medicine and therapeutic innovation","volume":"29","author":"Dhoundiyal","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1021\/acs.chemrev.6b00693","article-title":"Isotope tracers to study the environmental fate and bioaccumulation of metal-containing engineered nanoparticles: Techniques and applications","volume":"117","author":"Yin","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_132","first-page":"87","article-title":"From atomic nuclei to nanostructures: Harnessing the convergence of nuclear physics, particle dynamics, and nanotechnology to transform energy, revolutionize medicine, and advance environmental sustainability","volume":"4","author":"Hussain","year":"2025","journal-title":"Glob. Sci. Acad. Res. J. Multidiscip. Stud."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"21","DOI":"10.54660\/.IJMRGE.2025.6.2.21-32","article-title":"Public health risks associated with environmental radiation from improper medical waste disposal","volume":"6","author":"Adelodun","year":"2025","journal-title":"Int. J. Multidiscip. Growth Res. Eval."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Jalloul, W., Ghizdovat, V., Saviuc, A., Jalloul, D., Grierosu, I.C., and Stefanescu, C. (2025). Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081215"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Di Iorio, V., Sarnelli, A., Boschi, S., Sansovini, M., Genovese, R.M., Stefanescu, C., Ghizdovat, V., Jalloul, W., Young, J., and Sosabowski, J. (2025). Recommendations on the Clinical Application and Future Potential of \u03b1-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project. Pharmaceuticals, 18.","DOI":"10.20944\/preprints202508.0853.v1"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, D., dos Santos Augusto, R., Liang, J., Qin, Z., Liu, J., and Liu, Z. (2022). Production review of accelerator-based medical isotopes. Molecules, 27.","DOI":"10.3390\/molecules27165294"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2967\/jnumed.120.261016","article-title":"Production and supply of \u03b1-particle\u2013emitting radionuclides for targeted \u03b1-therapy","volume":"62","author":"Radchenko","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_138","first-page":"30","article-title":"Radionuclide generators: The prospect of availing PET radiotracers to meet current clinical needs and future research demands","volume":"9","author":"Dash","year":"2019","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100257","DOI":"10.1016\/j.ijft.2022.100257","article-title":"Ensuring security when using radioactive materials in a radiological facility","volume":"17","author":"Ansah","year":"2023","journal-title":"Int. J. Thermofluids"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1017\/erm.2022.6","article-title":"Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair","volume":"24","author":"Nikitaki","year":"2022","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.7150\/thno.113354","article-title":"Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells","volume":"15","author":"Nguyen","year":"2025","journal-title":"Theranostics"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Volterrani, D., Erba, P.A., Strauss, H.W., Mariani, G., and Larson, S.M. (2022). Radiobiology and radiation dosimetry in nuclear medicine. Nuclear Oncology, Springer.","DOI":"10.1007\/978-3-031-05494-5"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/jmri.25874","article-title":"Tumor radiomic heterogeneity: Multiparametric functional imaging to characterize variability and predict response following cervical cancer radiation therapy","volume":"47","author":"Bowen","year":"2018","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.124.269378","article-title":"Rethinking dosimetry: A European perspective","volume":"66","author":"Cicone","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Piwowarska-Bilska, H., Kurkowska, S., and Birkenfeld, B. (2022). Individualization of radionuclide therapies: Challenges and prospects. Cancers, 14.","DOI":"10.3390\/cancers14143418"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/med.22093","article-title":"Comparison of Radionuclide Drug Conjugates With Boron Neutron Capture Therapy: An Overview of Targeted Charged Particle Radiation Therapy","volume":"45","author":"Zhang","year":"2025","journal-title":"Med. Res. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7150\/thno.123376","article-title":"State-of-the-art boron clusters for boron neutron-capture therapy","volume":"16","author":"Wang","year":"2026","journal-title":"Theranostics"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Terranova, M.L. (2026). From Source to Target: The Neutron Pathway for the Clinical Translation of Boron Neutron Capture. J. Nucl. Eng., 7.","DOI":"10.3390\/jne7010006"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1017\/erm.2022.7","article-title":"Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT)","volume":"24","author":"Hughes","year":"2022","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Monti, H.A., and Hu, N. (2023). Optimizing boron neutron capture therapy (BNCT) to treat cancer: An updated review on the latest developments on boron compounds and strategies. Cancers, 15.","DOI":"10.3390\/cancers15164091"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1021\/acs.molpharmaceut.3c00701","article-title":"The dawn of a new era: Tumor-targeting boron agents for neutron capture therapy","volume":"20","author":"Luo","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1021\/acsomega.1c06603","article-title":"Gadolinium neutron capture therapy (GdNCT) agents from molecular to nano: Current status and perspectives","volume":"7","author":"Ho","year":"2022","journal-title":"ACS Omega"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jddst.2018.01.011","article-title":"Gadolinium nanoparticles as diagnostic and therapeutic agents: Their delivery systems in magnetic resonance imaging and neutron capture therapy","volume":"44","author":"Narmani","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100503","DOI":"10.1016\/j.ejro.2023.100503","article-title":"Gadolinium contrast agents-challenges and opportunities of a multidisciplinary approach: Literature review","volume":"11","author":"Iyad","year":"2023","journal-title":"Eur. J. Radiol. Open"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12032-025-03061-0","article-title":"Theranostics in nuclear medicine: The era of precision oncology","volume":"42","author":"Gandhi","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Rathmann, S.M., Ahmad, Z., Slikboer, S., Bilton, H.A., Snider, D.P., and Valliant, J.F. (2019). The radiopharmaceutical chemistry of technetium-99m. Radiopharmaceutical Chemistry, Springer.","DOI":"10.1007\/978-3-319-98947-1_18"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:17:43Z","timestamp":1772515063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":157,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052290"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052290","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}